The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XXIII.e

Rechallenge may not necessarily lead to relapse of AE/ILD

Publications

Bickert C, Kahnert K, Kauffmann-Guerrero D, Götschke J, Syunyaeva Z, Behr J, Tufman A

Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies.

Therapeutic advances in medical oncology 2021;13;17588359211018028 — 2021 — 17588359211018028

Mohammed T, Mangeshkar S, Rathmann J

Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis.

Case reports in oncology 2021 May-Aug;14;733-738 — 2021 May-Aug — 733-738

Kodama H, Wakuda K, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T

Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.

Investigational new drugs 2021 04;39;571-577 — 2021 04 — 571-577